Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility M. Bogdan, A. Eliraz, C. Mckinnon, U. Nihlen, E. Radeczky, S. Soliman, D. Osmanliev (Bucharest, Romania; Rehovot, Israel; Glasgow, United Kingdom; Lund, Sweden; Százhalombatta, Hungary; Sofia, Bulgaria)
Source: Annual Congress 2002 - COPD - Drug therapy 1
Session: COPD - Drug therapy 1 Session type: Thematic Poster Session Number: 1578
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Bogdan, A. Eliraz, C. Mckinnon, U. Nihlen, E. Radeczky, S. Soliman, D. Osmanliev (Bucharest, Romania; Rehovot, Israel; Glasgow, United Kingdom; Lund, Sweden; Százhalombatta, Hungary; Sofia, Bulgaria). Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility. Eur Respir J 2002; 20: Suppl. 38, 1578
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Tiotropium as essential maintenance therapy in COPD Source: Eur Respir Rev 2006; 15: 51-57 Year: 2006
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011
Tiotropium added to theophylline improves lung function in patients with chronic obstructive pulmonary disease rapidly, compared to theophylline alone Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007